Still Alice Page 0,33

if she’d known that she carried this gene, this fate, in every cell of her body? Would she have conceived these children or taken precautions to prevent them? Would she have been willing to risk the random roll of meiosis? Her amber eyes, John’s aquiline nose, and her presenilin-1. Of course, now, she couldn’t imagine her life without them. But before she had children, before the experience of that primal and previously inconceivable kind of love that came with them, would she have decided it would be better for everyone not to? Would Anna?

Tom walked in, with apologies for being late and without his new girlfriend. It was just as well. Today should be just the family. And Alice couldn’t remember her name. He made a beeline for the dining room, likely worried that he’d missed out on the food, then returned to the living room with a grin on his face and a plate heaping with some of everything. He sat on the couch next to Lydia, who had her script in her hand and her eyes closed, silently mouthing her lines. They were all there. It was time.

“Your dad and I have something important we need to talk to you about, and we wanted to wait until we had all three of you together.”

She looked to John. He nodded and squeezed her hand.

“I’ve been experiencing some difficulties with my memory for some time now, and in January, I was diagnosed with early-onset Alzheimer’s disease.”

The clock on the fireplace mantel ticked loudly, like someone had turned its volume up, the way it sounded when no one else was in the house. Tom sat frozen with a forkful of frittata midway between his plate and mouth. She should have waited until he’d finished eating his brunch.

“Are they sure it’s Alzheimer’s? Did you get a second opinion?” he asked.

“She had genetic screening. She has the presenilin-1 mutation,” said John.

“Is it autosomal dominant?” asked Tom.

“Yes.”

He said more to Tom, but only with his eyes.

“What does that mean? Dad, what did you just tell him?” Anna asked.

“It means we have a fifty percent chance of getting Alzheimer’s disease,” said Tom.

“What about my baby?”

“You’re not even pregnant,” said Lydia.

“Anna, if you have the mutation, it’s the same for your children. Each child you have would have a fifty percent chance of inheriting it, too,” said Alice.

“So what do we do? Do we go get tested?” asked Anna.

“You can,” said Alice.

“Oh my god, what if I have it? And then my baby could have it,” said Anna.

“There’ll probably be a cure by the time any of our kids would need it,” said Tom.

“But not in time for us, is that what you’re saying? So my kids will be fine, but I’ll be a mindless zombie?”

“Anna, that’s enough!” John snapped.

His jaw clenched, and his face flushed. A decade ago, he would’ve sent Anna to her room. Instead, he gave Alice’s hand a hard squeeze and jiggled his leg. In so many ways, he’d become powerless.

“Sorry,” said Anna.

“It’s very likely that there’ll be a preventative treatment by the time you’re my age. That’s one of the reasons to know if you have the mutation. If you do, you might be able to go on a medication well before you’re symptomatic and, hopefully, you never will be,” said Alice.

“Mom, what kind of treatment do they have now, for you?” asked Lydia.

“Well, they have me on antioxidant vitamins and aspirin, a statin, and two neurotransmitter drugs.”

“Are those going to keep the Alzheimer’s from getting any worse?” asked Lydia.

“Maybe, for a little while, they don’t really know for sure.”

“What about what’s in clinical trials?” asked Tom.

“I’m looking into that now,” said John.

John had begun talking to clinicians and scientists in Boston who researched the molecular etiology of Alzheimer’s, getting their perspectives on the relative promise of the therapies in the clinical pipeline. John was a cancer cell biologist, not a neuroscientist, but it wasn’t a huge leap for him to understand the cast of molecular criminals run amok in another system. They all spoke the same language—receptor binding, phosphorylation, transcriptional regulation, clathrin-coated pits, secretases. Like owning a membership card to the most exclusive club, being from Harvard gave him instant credibility with and access to the most respected thought leaders in Boston’s Alzheimer’s research community. If a better treatment existed or might exist soon, John would find it for her.

“But Mom, you seem perfectly fine. You must’ve caught this really early on, I wouldn’t even know anything was wrong,” said